Damora Therapeutics Inc Net Income per Employee (DMRA), current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket
 


Damora Therapeutics Inc   (NASDAQ: DMRA)
 

Damora Therapeutics Inc Net Income per Employee

DMRA's Quarterly Results, Trends, Rankings, Statistics
Damora Therapeutics Inc recorded a cumulative net loss of $-62 million during 12 month ending in the second quarter 2026.
The Healthcare sector has seen Damora Therapeutics Inc achieved the highest income per employee. While Damora Therapeutics Inc 's total ranking has deteriorated compared to the previous quarter from 3 to 4.


What is Income per Employee Ratio?






DMRA Net Income per Employee (Jun 30 2026)
II. Quarter
(Mar 31 2026)
I. Quarter
(Dec 31 2025)
IV. Quarter
(Sep 30 2025)
III. Quarter
(Jun 30 2025)
II. Quarter
Y / Y Net Income Change - - - - -
Net Income per Employee (TTM) $ -8,873,714 -4,907,571 -1,300,429 -2,263,429 -2,370,571
DMRA's Total Ranking # 4 # 3 # 0 # #
Seq. Net Income Change - - - - -


DMRA Net Income per Employee Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 0
Healthcare Sector # 0
Overall Market # 4

Net Income per Employee Statistics
High Average Low
$ -1,664,429 $ -5,239,977 $ -8,803,429
(Sep 30 2020)   (Dec 31 2022)







Companies with similar Income per Employee for 12 month ending Jun 30 2026, within Healthcare Sector Income per Employee Income 12 month ending Jun 30 2026Number of Employees Jun 30 2026


Date modified: 2026-08-13T08:19:50+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.